Literature DB >> 21675836

Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.

Amy Guppy1, Mariam Jamal-Hanjani, Lisa Pickering.   

Abstract

Metformin is an orally available, biguanide derivative that is widely used in the treatment of Type 2 diabetes. Recent preclinical data have demonstrated that it can also act as an anticancer agent by activation of AMPK and subsequent inhibition of mTOR. Metformin is currently being investigated in several Phase II/III clinical trials. This article will review the current evidence for its mechanism of action, efficacy in preclinical and clinical models, and toxicity. Ongoing and planned studies evaluating the impact of metformin on breast cancer outcomes are also discussed.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21675836     DOI： 10.2217/fon.11.49

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


  14 in total

Review 1.  Metabolic implication of tumor:stroma crosstalk in breast cancer.

Authors:  Andrea Morandi; Paola Chiarugi
Journal:  J Mol Med (Berl)       Date:  2014-01-24       Impact factor: 4.599

Review 2.  Nutrient restriction and radiation therapy for cancer treatment: when less is more.

Authors:  Colin E Champ; Renato Baserga; Mark V Mishra; Lianjin Jin; Federica Sotgia; Michael P Lisanti; Richard G Pestell; Adam P Dicker; Nicole L Simone
Journal:  Oncologist       Date:  2013-01-08

Review 3.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Feras Zaiem; Fazlul H Sarkar
Journal:  Ann Transl Med       Date:  2014-06

Review 4.  Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy.

Authors:  Shreya Mitra; Katherine Stemke-Hale; Gordon B Mills; Sofie Claerhout
Journal:  Cancer Sci       Date:  2012-01-30       Impact factor: 6.716

Review 5.  Diabetes and sex: from pathophysiology to personalized medicine.

Authors:  Rosanna Abbate; Edoardo Mannucci; Gabriele Cioni; Cinzia Fatini; Rossella Marcucci
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

6.  Preventive effect of Metformin against N-nitrosodiethylamine-initiated hepatocellular carcinoma in rats.

Authors:  Muhammad Afzal; Imran Kazmi; Gaurav Gupta; Mahfoozur Rahman; Vishwadeepak Kimothi; Firoz Anwar
Journal:  Saudi Pharm J       Date:  2012-06-09       Impact factor: 4.330

7.  Recruitment strategies, design, and participant characteristics in a trial of weight-loss and metformin in breast cancer survivors.

Authors:  Ruth E Patterson; Catherine R Marinac; Loki Natarajan; Sheri J Hartman; Lisa Cadmus-Bertram; Shirley W Flatt; Hongying Li; Barbara Parker; Jesica Oratowski-Coleman; Adriana Villaseñor; Suneeta Godbole; Jacqueline Kerr
Journal:  Contemp Clin Trials       Date:  2015-12-17       Impact factor: 2.226

8.  Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells.

Authors:  Lakshmipathi Vadlakonda; Mukesh Pasupuleti; Reddanna Pallu
Journal:  Front Oncol       Date:  2013-04-12       Impact factor: 6.244

9.  The influence of metformin in the etiology of selected cancers.

Authors:  Monika Pawałowska; Anna Markowska
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06

10.  Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction.

Authors:  Rakhshanda Layeequr Rahman; Sandhya Pruthi
Journal:  Cancers (Basel)       Date:  2012-10-29       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.